MedCity News September 27, 2021
Frank Vinluan

Delix Therapeutics is developing drugs that offer the therapeutic benefits of psychedelic drugs, but without the hallucinations and other side effects that accompany these compounds. The startup has closed $70 million in Series A financing as it works to bring its lead candidates into the clinic next year.

Psychedelic drugs can treat mood disorders, but hallucinations and a range of other side effects limit their use. Delix Therapeutics is developing small molecules that could avoid such hallucinogenic effects. The startup’s lead drug candidates are on track to reach human testing next year and Delix has raised $70 million to support that work.

The Series A round of funding announced Monday was led by ARTIS Ventures, RA Capital Management, and founding...

Today's Sponsors

ZeOmega
Holon
Transcarent

Today's Sponsors

Crossover Health
Qure4u

Today's Sponsor

Institute for Healthcare Improvement

 
Topics: Biotechnology, Investments, Pharma, Pharma / Biotech, Trends
Xilio, Ventyx IPOs raise $269M to fuel plans to compete with big pharma drugs
How are the European pharma and biotech sectors addressing strategic communications?
FDA Highlights Value and Challenges of Advanced Drug Manufacturing
Drug overdoses surged during the pandemic. Providers are thinking outside the box to combat the opioid crisis
Ways Decentralized Clinical Trials Can Expand Diversity & Improve Participation Rates